Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice

Tina Fløyel; Caroline Frørup; Martin Haupt-Jorgensen; Laurits Juulskov Holm; Kristina Pedersen; Mia Øgaard  Mønsted; Karsten Stig Buschard; Joachim Størling; Flemming Pociot

Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice

Tina Fløyel, Caroline Frørup, Martin Haupt-Jorgensen, Laurits Juulskov Holm, Kristina Pedersen, Mia Øgaard Mønsted, Karsten Stig Buschard, Joachim Størling, Flemming Pociot

Abstract

Originalsprog	Engelsk
Artikelnummer	210
Tidsskrift	Diabetologia
Vol/bind	65
Udgave nummer	SUPPL 1
Sider (fra-til)	S109-S110
Antal sider	1
ISSN	0012-186X
Status	Udgivet - 31 aug. 2022
Begivenhed	58th EASD Annual Meeting of the European Association for the Study of Diabetes - Stockholm, Sverige Varighed: 19 sep. 2022 → 23 sep. 2022

Konference

Konference	58th EASD Annual Meeting of the European Association for the Study of Diabetes
Land/Område	Sverige
By	Stockholm
Periode	19/09/2022 → 23/09/2022

Adgang til dokumentet

https://link.springer.com/article/10.1007/s00125-022-05755-w

Citationsformater

Fløyel, T., Frørup, C., Haupt-Jorgensen, M., Holm, L. J., Pedersen, K., Mønsted, M. Ø., Buschard, K. S., Størling, J., & Pociot, F. (2022). Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice. Diabetologia, 65(SUPPL 1), S109-S110. Artikel 210. https://link.springer.com/article/10.1007/s00125-022-05755-w

Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice. / Fløyel, Tina; Frørup, Caroline; Haupt-Jorgensen, Martin et al.
I: Diabetologia, Bind 65, Nr. SUPPL 1, 210, 31.08.2022, s. S109-S110.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Fløyel, T, Frørup, C, Haupt-Jorgensen, M, Holm, LJ, Pedersen, K , Mønsted, MØ , Buschard, KS , Størling, J & Pociot, F 2022, 'Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice', Diabetologia, bind 65, nr. SUPPL 1, 210, s. S109-S110. <https://link.springer.com/article/10.1007/s00125-022-05755-w>

@article{e06475a9989d4061a5b718113e740c30,

title = "Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice",

author = "Tina Fl{\o}yel and Caroline Fr{\o}rup and Martin Haupt-Jorgensen and Holm, {Laurits Juulskov} and Kristina Pedersen and M{\o}nsted, {Mia {\O}gaard} and Buschard, {Karsten Stig} and Joachim St{\o}rling and Flemming Pociot",

year = "2022",

month = aug,

day = "31",

language = "English",

volume = "65",

pages = "S109--S110",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "SUPPL 1",

note = "58th EASD Annual Meeting of the European Association for the Study of Diabetes ; Conference date: 19-09-2022 Through 23-09-2022",

}

TY - ABST

T1 - Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice

AU - Fløyel, Tina

AU - Frørup, Caroline

AU - Haupt-Jorgensen, Martin

AU - Holm, Laurits Juulskov

AU - Pedersen, Kristina

AU - Mønsted, Mia Øgaard

AU - Buschard, Karsten Stig

AU - Størling, Joachim

AU - Pociot, Flemming

PY - 2022/8/31

Y1 - 2022/8/31

M3 - Conference abstract in journal

SN - 0012-186X

VL - 65

SP - S109-S110

JO - Diabetologia

JF - Diabetologia

IS - SUPPL 1

M1 - 210

T2 - 58th EASD Annual Meeting of the European Association for the Study of Diabetes

Y2 - 19 September 2022 through 23 September 2022

ER -